Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France. Show more

Location: 50 rue de Dijon, Daix, 21121, France | Website: https://inventivapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

465.8M

52 Wk Range

$1.53 - $4.05

Previous Close

$3.38

Open

$3.44

Volume

20,641

Day Range

$3.30 - $3.44

Enterprise Value

389.5M

Cash

96.91M

Avg Qtr Burn

-21.48M

Insider Ownership

0.00%

Institutional Own.

5.09%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.